Extracellular vesicle engineering using a small scaffold protein - PubMed
12 hours ago
- #Inflammatory Diseases
- #Drug Delivery
- #Extracellular Vesicles
- Extracellular vesicles (EVs) are promising drug-delivery vehicles due to their biocompatibility and low immunogenicity.
- ENPP1 was identified as a superior scaffold protein for EV engineering, with a truncated variant, EN144, showing high efficiency in loading therapeutic cargoes.
- EN144 was fused to the IL-6 decoy receptor gp130 to create engineered decoy EVs that inhibit inflammatory IL-6 trans-signaling.
- In mouse models, these engineered EVs reduced inflammation, improved survival in sepsis, and alleviated tissue damage in osteoarthritis when targeted to cartilage.
- The research has been filed for a patent, and some authors have affiliations with EVLiXiR Biotech Inc.